Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,662.67
(
-0.80%
)
US TECH 100
23,989.60
(
-0.59%
)
Dow Jones
46,453.32
(
-1.15%
)
Brent Oil
104.98
(
4.30%
)
Bitcoin
71,676.44
(
-3.06%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: NP1986 post# 123980

Tuesday, 07/26/2011 11:11:34 PM

Tuesday, July 26, 2011 11:11:34 PM

Post# of 257253

GILD/JNJ/BMY—It's not very surprising since there were question marks about Edurant's efficacy in comparison to Sustiva. I don't think Btripla will cannibalize Atripla sales to a great extent - there might be some usage in patients who have neuropsychiatric side effects with Atripla, but I don't envision much first line usage at all.

The other advantage of Btripla vs Atripla: Edurant is Pregnancy Category B (no known risk), while Sustiva is Pregnancy Category D (empirical evidence of fetal risk).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now